BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

BriaCell Therapeutics Corp. (BCTX, BCTXL), a clinical-stage biotechnology company, on Wednesday announced the pricing of a public offering of 5.367 million units at $5.59 per unit, for gross proceeds of approximately $30 million.Each unit consists of one common share and one warrant. Each warrant will be immediately exercisable, entitle the holder to purchase one common share at an exercise price of $6.93 per share, and will expire five years from the date of issuance. Following the announcement in the pre ...